A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DMPA / depot medroxyprogesterone acetate

[Related PubMed/MEDLINE]
Total Number of Papers: 554
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DMPA  (>> Co-occurring Abbreviation)
Long Form:   depot medroxyprogesterone acetate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 ACOG Practice Bulletin No. 206 Summary: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. HIV, USMEC
2019 ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. HIV, USMEC
2019 Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High-risk African Women. HIV-1, IUDs, STIs
2019 Being on the Safe Side: A Qualitative Study of Condom Use Motivations by Contraceptive Type among Adolescents in Atlanta, GA. LARC, STI
2019 Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women. F/B, L/P, VNAB
2019 Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users. CV, OCP, PKs
2019 Effects of three long-acting reversible contraceptive methods on HIV target cells in the human uterine cervix and peripheral blood. ETG, LNG-IUD
2019 Factors associated with provision of depot medroxyprogesterone acetate to adolescents by US health care providers. AORs, CIs
2019 Health Care Provider Attitudes and Practices Related to 'Quick Start' Provision of Combined Hormonal Contraception and Depot Medroxyprogesterone Acetate to Adolescents. AORs, CHC, CIs
10  2019 Hormonal contraceptives and the acquisition of sexually transmitted infections: an updated systematic review. HC, HPV, HSV-2, NET-EN, STIs
11  2019 Increased Cervical CD4+CCR5+ T Cells Among Kenyan Sex Working Women Using Depot Medroxyprogesterone Acetate. ---
12  2019 Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate: A Systematic Review. ---
13  2019 Thyroid function during the first year of use of the injectable contraceptive depot medroxyprogesterone acetate. BMI, IUD
14  2019 Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum. VTE
15  2018 A Longitudinal Assessment of Cervical Inflammation and Immunity Associated with HIV-1 Infection, Hormonal Contraception, and Pregnancy. COCs, HC, RANTES, SLPI
16  2018 Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status. BMD, BMI, COCs, FSH, NET-EN
17  2018 Cause or Coincidence? Spontaneous Hematometra in Young Women Receiving Depomedroxyprogesterone Acetate: A Small Case Series. ---
18  2018 Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives. BV, COC, LNG-IUS, STIs
19  2018 Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. FDA, NETA, PK
20  2018 Decreasing trends in number of depot medroxyprogesterone acetate starters in Norway - a cross-sectional study. ---
21  2018 Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review. ---
22  2018 Differential expressions of estrogen and progesterone receptors in endometria and cyst walls of ovarian endometrioma from women with endometriosis and their responses to depo-medroxyprogesterone acetate treatment. ERs, PRs
23  2018 Exogenous oestrogen inhibits genital transmission of cell-associated HIV-1 in DMPA-treated humanized mice. DSG-1, hPBMC-NSG, hPBMCs, HSV-2, IVAG, LMW, NSG
24  2018 Exposure to routine availability of immediate postpartum LARC: effect on attitudes and practices of labor and delivery and postpartum nurses. LARC
25  2018 Hyperinsulinemic-euglycemic clamp over the first year of use of depot-medroxyprogesterone acetate as a contraceptive. HEC, IR, IUD
26  2018 MOBILE-izing Adolescent Sexual and Reproductive Health Care: A Pilot Study Using a Mobile Health Unit in Chicago. EC, MHUs, OCPs, SRHC
27  2018 Progestin-based contraception regimens modulate expression of putative HIV risk factors in the vaginal epithelium of pig-tailed Macaques. COCs, EE, LNG, SHIV
28  2018 Risk factors for ectopic pregnancy in a population of Cameroonian women: A case-control study. AOR, CIs, EP, IUP, LNG-EC, OR, PID
29  2018 Subclinical cardiovascular disease parameters after one year in new users of depot medroxyprogesterone acetate compared to copper-IUD. ANOVA, BMI, IUD
30  2018 Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity. COC, IPA, USAID
31  2018 Why Didn't You Text Me? Poststudy Trends From the DepoText Trial. RCT
32  2017 A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities. ART, LNG
33  2017 Body composition, resting energy expenditure and inflammatory markers: impact in users of depot medroxyprogesterone acetate after 12 months follow-up. BMR, BS, REE, RQ
34  2017 Bone Mineral Density and Weight Changes in Adolescents Randomized to 3 Doses of Depot Medroxyprogesterone Acetate. BMD
35  2017 Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact oftheboxed warning. BMD, BPA, CHC
36  2017 Community Health Workers as Social Marketers of Injectable Contraceptives: A Case Study from Ethiopia. CBD, HEWs
37  2017 Contraception Insurance Coverage and Receipt of Long-Acting Reversible Contraception or Depot Medroxyprogesterone Acetate on the Day of Abortion. ---
38  2017 Contraception Update: Progestin-Only Implants and Injections. ---
39  2017 Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. COCs, HR
40  2017 Correlation between uterine artery Doppler indices and menstrual irregularities among levonorgestrel releasing intrauterine system and depot medroxyprogesterone acetate users: a prospective observational study. LNG-IUS, PI, RI
41  2017 Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users. BMI, IUD
42  2017 Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. AOR, BV, CI, COCs, LNG-IUS, STIs
43  2017 Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. IPC, IUD, RCT
44  2017 Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study. CI
45  2017 Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices. ---
46  2017 Healthcare Provider Attitudes Regarding Contraception for Women with Obesity. AORs, CIs, COCs, IUDs, LNG
47  2017 High dose of green tea infusion normalized spiral artery density in rats treated with the depot-medroxyprogesterone acetate. GT
48  2017 High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception. OCP
49  2017 Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. Yc
50  2017 Postpartum family planning: missed opportunities across the continuum of care FP, RDHS
51  2017 Psychological, behavioural and physiological effects of three long-acting reversible contraception (LARC) methods: protocol for an ancillary study of the ECHO randomised trial. ECHO, IUD, LARC, LNG
52  2017 Repeated administration of high-dose depot medroxyprogesterone acetate does not alter SHIVSF162p3 viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings. IVR, TDF, TFV
53  2017 The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. ---
54  2017 Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding. CSPG4, ELISA, HEECs, HESC, PCR, rh
55  2017 Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection. HIV, U.S. MEC, WHO
56  2017 Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada. HSV-2, PY
57  2016 A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk. SHIV, SIV
58  2016 Adolescent Contraception Before and After Pregnancy-Choices and Challenges for the Future. CAISM, LARCs
59  2016 An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. ---
60  2016 Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness. aHR, ART, CI, COCs, IUD
61  2016 Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate. BES, BMI, IUD
62  2016 Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate. LDL
63  2016 Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate. IL
64  2016 Comparison of two strategies for the administration of injectable depot medroxyprogesterone acetate: among women who returned to a family planning clinic at three- or six-month intervals. ---
65  2016 Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery. VTE
66  2016 DMPA Suppresses Cell Proliferation and Enhances Cell Apoptosis of Eutopic Endometrium in Women with Endometriosis: A Randomized Controlled Study. ---
67  2016 Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. AA, BMD, EDI, OCs
68  2016 Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. cART, CMI, MPA, Treg
69  2016 Injectable contraception: updates and innovation. ---
70  2016 Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use. BMI, HOMA, HOMA-IR
71  2016 Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States. AOR, CI, DMPA-SC
72  2016 Long-Term Clinical Outcomes in Diabetic Rhesus Macaques (Macaca mulatta) Treated with Medroxyprogesterone Acetate for Endometriosis. DM
73  2016 Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. DSG1alpha, HSV-2, LNG, STI
74  2016 Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial. MPA
75  2016 Predictors of Early Discontinuation of Effective Contraception by Teens at High Risk of Pregnancy. CI, COCs, HR, IUD
76  2016 Progestin-based contraceptive on the same day as medical abortion. ---
77  2016 Progestin-only contraception and thromboembolism: A systematic review. AMI, LNG-IUDs, POCs, POPs, VTE
78  2016 Progestin-only contraceptives: effects on weight. CI, LNG-IUC, MD, NRS, OR, POCs
79  2016 Protective Effect of Vitamins C and E on Depot-Medroxyprogesterone Acetate-Induced Ovarian Oxidative Stress In Vivo. ELISA, MDA
80  2016 Safety and Acceptability of Community-Based Distribution of Injectable Contraceptives: A Pilot Project in Mozambique. APEs, TBAs
81  2016 Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. COCs, IUDs, OCs
82  2016 The Effect of Depo Medroxyprogesterone Acetate (DMPA) on Cerebral Food Motivation Centers: A Pilot Study using Functional Magnetic Resonance Imaging. BOLD, fMRI
83  2016 The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. EPDS, IUD, PND
84  2016 The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. IM, MEC, SC, WHO
85  2016 Women's experiences after Planned Parenthood's exclusion from a family planning program in Texas. NSFG
86  2015 Analysis of putative mucosal SHIV susceptibility factors during repeated DMPA treatments in pigtail macaques. ---
87  2015 CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception. HIV, LNG-IUD
88  2015 Characterization of tubal occlusion after transcervical polidocanol foam (PF) infusion in baboons. PF
89  2015 Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. CENTRAL, CI, COCs, LNG-IUS, MD, mL, OR, POPs
90  2015 Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate (DMPA) and Cyclofem. FSFI
91  2015 Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. ACTG, LPV, MPA, PK, RTV
92  2015 Depot Medroxyprogesterone Acetate Use Is Associated With Elevated Innate Immune Effector Molecules in Cervicovaginal Secretions of HIV-1-Uninfected Women. ---
93  2015 Dietary Intake and Weight Gain Among Adolescents on Depot Medroxyprogesterone Acetate. BMI
94  2015 Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract. COC, IFN, pDCs
95  2015 Effectiveness of evidence-based medicine on knowledge, attitudes, and practices of family planning providers: a randomized experiment in Jordan. EBM
96  2015 Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model. HSV-2
97  2015 Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women. AOR, HIV, NCDs
98  2015 Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. aHR, COCs, HC, IPD, NET-EN
99  2015 Hormonal contraceptive use and women's risk of HIV acquisition: priorities emerging from recent data. NET-EN
100  2015 Impact of Reminder Systems in Clinical Settings to Improve Family Planning Outcomes: A Systematic Review. OC